Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of Buy from Analysts

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been assigned a consensus recommendation of “Buy” from the four research firms that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock […]

Related Keywords

Canada ,United States ,America ,Michael Crowley ,Adara Wright ,Bio Rad Laboratories Inc ,Financial Services ,Bio Rad Laboratories Company Profile ,Raleigh Capital Management Inc ,Pacific Center ,Atlas Capital Advisors ,Bio Rad Laboratories ,Get Free Report ,Finance Advisors ,Capital Management ,Rad Laboratories ,Get Free ,Life Science ,Clinical Diagnostics ,Bio Rad Laboratories Daily ,Nyse Bio ,Bio ,Medical ,09057220 ,Ratings ,Consensus ,